Showing results (511-520 of 579) with videos related to
Sort By:
Pageof 58
Cancer|October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutationsMahran Shoukier, Tapan Kadia, Marina Konopleva, et al.American Journal of Hematology|June 19, 2023
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantationAlexandre Bazinet, Hagop Kantarjian, Naszrin Arani, et al.Blood Advances|November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLGhayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.JCO Oncology Practice|July 16, 2024
Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisFadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.Journal of Hematology & Oncology|June 17, 2026
Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasmsSankalp Arora, Jayastu Senapati, Indraneel Deshmukh, et al.Journal of Hematology & Oncology|January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposureNicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.Cancer|August 3, 2021
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysisAbhishek Maiti, Courtney D DiNardo, Wei Qiao, et al.Blood Advances|April 22, 2021
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclaxCurtis A Lachowiez, Sanam Loghavi, Ken Furudate, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2023
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid MalignanciesJayastu Senapati, Warren C Fiskus, Naval Daver, et al.Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.Pageof 58